8-K current report · filed Aug 6, 2026

PUMA BIOTECHNOLOGY, INC. (PBYI) 8-K Current Report: August 6, 2026

Item EX-99.1Item 2.02PBYI overview

Short answer

PUMA BIOTECHNOLOGY, INC. (PBYI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for the quarter ended June 30, 2026 announced.

PUMA BIOTECHNOLOGY, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for the quarter ended June 30, 2026 announced
  • Full operating results and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $56.5M, up from $52.4M, led by NERLYNX product revenue of $53.6M versus $49.2M
  • Q2 GAAP net income $8.2M, or $0.16 per diluted share, versus $5.9M and $0.12
  • Full-year 2026 revenue guidance raised to $224M-$231M, with net income guidance increased to $17M-$20M
  • Debt reduced to zero after final 2021 Note Purchase Agreement payment, supporting financial flexibility
  • Cash, equivalents and marketable securities $93.9M at June 30, while R&D rose to $38.7M through six months for alisertib development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PUMA BIOTECHNOLOGY, INC. 8-K filings

Get the next PBYI 8-K as it lands

Follow PBYI for push alerts, or ask the research agent what this filing means.